European countries prepared on April 21 to resume deliveries of Johnson & Johnson’s Covid-19 vaccine and speed up the rollout after Europe’s drug regulator backed the shot.
Johnson & Johnson said on April 20 the company will resume rolling out its Covid-19 vaccine in Europe after the region’s medical regulator said the benefits of the shot outweigh the risk of very rare, potentially lethal blood clots.
Europe’s drug regulator found a possible link between Johnson & Johnson’s Covid-19 vaccine and rare blood clotting issues in adults who received doses in the United States, but backed its overall benefits against any risks.
The European Medicines Agency (EMA) said on April 7 it had found a possible link between AstraZeneca’s coronavirus vaccine and reports of very rare cases of blood clots in people who had received the shot.
The European Commission granted Amarin Corporation Plc’s fish-oil derived heart drug Vazkepa marketing authorization in the European Union, the drugmaker said on March 30.
Copenhagen, Denmark-based Orphazyme announced the company’s Phase II/III clinical trial of arimoclomal for inclusion body myositis (IBM) failed to hit primary and secondary endpoints.
GSK and Vir Biotechnology filed an application to U.S. regulators for emergency use authorization of their antibody therapy to treat early-stage Covid-19 infections, the drugmakers said on March 26.
Scientists are exploring several possibilities that might explain at least 18 reports of extremely rare blood clots in the brain that occurred in individuals in the days and weeks after receiving the AstraZeneca COVID-19 vaccine.
A World Health Organization (WHO) vaccine safety panel said on March 17 that it considers that the benefits of the AstraZeneca Covid-19 vaccine outweigh its risks and recommends that vaccinations continue.
AstraZeneca Plc said on March 14 a review of safety data of people vaccinated with the company’s Covid-19 vaccine has shown no evidence of an increased risk of blood clots.
